## Investigation of Choice for Assessing Ovarian Reserve in PCOS **Key Point:** Serum anti-müllerian hormone (AMH) is the most appropriate investigation to assess ovarian reserve and predict response to ovulation induction in PCOS patients because it reflects the pool of primordial and small antral follicles. ### Why AMH Is Superior in PCOS **High-Yield:** AMH is particularly valuable in PCOS because: - It is **cycle-independent** — can be measured at any time during the menstrual cycle (unlike FSH, which requires day 3 measurement) - It is **not affected by hormonal contraceptives** — patients with PCOS often use OCPs before fertility evaluation - It **reflects actual follicle pool** — directly correlates with antral follicle count and ovarian reserve - It is **more stable** — less day-to-day variation than FSH ### Interpretation and Clinical Use | AMH Level | Ovarian Reserve | Clomiphene Response | |---|---|---| | >3.0 ng/mL | Normal to high | Good responder; may have PCOS | | 1.5–3.0 ng/mL | Normal | Expected response | | 0.5–1.5 ng/mL | Low | Suboptimal response; consider gonadotropins | | <0.5 ng/mL | Very low | Poor responder; consider IVF with higher doses | **Clinical Pearl:** In PCOS specifically, AMH is often **elevated** (>3.0 ng/mL) due to increased number of small follicles. This predicts good ovarian response but also increased risk of ovarian hyperstimulation syndrome (OHSS) — important for counseling and dose adjustment. ### Mechanism AMH is produced by granulosa cells of small antral follicles. Higher levels indicate a larger pool of recruitable follicles, predicting better ovulation induction response and lower miscarriage risk. **Mnemonic:** **AMH = Antral Follicle Marker** — it quantifies the pool of small follicles available for recruitment during ovulation induction.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.